BioNTech SE and Pfizer Inc. are working together on an effective vaccine against the Omicron variant of the coronavirus. These companies promise to present the finished product by March 2022.
According to a press release on the website of the American pharmaceutical company, the serum antibodies produced by the Pfizer-BioNTech vaccine will neutralize this new variant of COVID-19 after three doses. And in the case of two doses, the neutralizing antibodies’ activeness against Omicron is 25 times lower.
Additional research by these companies shows that the current booster shots of Pfizer and BioNTech increase antibody titers by 25 times.